Where should TQC3721 compete in COPD?
The question brought together several choices: which patients to study, which formulation to advance and how to establish a position alongside ensifentrine, an approved therapy in the same class. Quinn assessed the published clinical evidence, candidate populations and formulation requirements together.
Similar estimates.
Different trial contexts.
Average 12-hour FEV₁ gain versus placebo.
87 mL
87 mL
94 mL
Gain versus each trial’s placebo group (mL)
The context matters. PACER-II included dual bronchodilators. ENHANCE excluded dual and triple therapy. Timing and treatment context differ; these estimates do not establish equivalence.
He et al., CHEST 2026 ↗Anzueto et al., AJRCCM 2023 ↗
FEV₁: air exhaled in the first second of a forced breath. CI: confidence interval.
The evidence left two populations open.
The assessment found that the reviewed public data did not support choosing between the two leading populations or selecting a lead formulation. The trials also differed in ways that prevented a reliable numerical comparison between the programs.
The work identified what a prospective study would need to resolve before population and formulation choices could be made. It separated the molecule’s reported activity from the evidence still needed for a development decision.
That is the practical value of the work: a clear view of what the evidence supports, what it leaves open and what to investigate next. The proposed study still required a complete design and prospective evidence; the assessment did not establish comparative efficacy or a clinical outcome.